GSTM1 and Schnyder corneal dystrophy: The US FDA has approved Voxelotor for treating adults and children (≥4 years of age) with SCD based on the results from the HOPE and HOPE-KIDs trials, where it demonstrated an improved Hb level, and reduced hemolysis, with an improved rate of vaso-oclusive crises (VOCs) (3, 4).